Core Viewpoint - The healthcare services sector experienced a 1.3% increase in value with a net capital inflow of 619 million, indicating positive market sentiment towards the industry [1] Sector Performance - The healthcare services sector saw 31 stocks rise while 13 stocks declined on the reporting day [1] - The top ten decliners in the sector included Chengda Pharmaceutical (-13.12%), Chengdu Xian Dao (-2.8%), Huakang Clean (-2.62%), and others, reflecting a mixed performance within the industry [1] Notable Stocks - Key stocks with significant movements included: - Maipu Medical: Current price 68.25, up 10.58%, with a net capital inflow of 1.77 million [1] - Medicy: Current price 64.59, up 8.83%, with a net capital inflow of 2.49 million [1] - He Yuan Biological: Current price 8.07, up 8.61%, with a net capital inflow of 4.05 million [1] - Other notable stocks included Zhaoyan New Drug, Kailai Ying, and Kanglong Chemical, each showing varying degrees of price increases and capital inflows [1]

New Stock Issuance - New stock issued by Dingjia Precision at a price of 11.16 on July 22, 2025[1] - ST Kelly's tender offer period is from July 17 to August 15, 2025[1] - ST Zitian and other companies have also announced new stock issuances[1] Market Alerts - Significant abnormal fluctuations reported for several stocks including Guangshengtang and Huayin Power[1] - Multiple companies have disclosed announcements regarding stock performance and market activities[1] - The report includes links to detailed announcements for various stocks, indicating ongoing market monitoring[1]

Group 1 - The innovative drug sector is experiencing a resurgence, with significant stock price increases for companies such as Chengda Pharmaceutical (+14.05%) and Huisheng Pharmaceutical (+9.45%) [1][2] - The National Healthcare Security Administration (NHSA) is actively promoting high-quality development of innovative drugs through a series of meetings and discussions with industry representatives [3] - The NHSA's commitment to supporting genuine innovation and establishing a comprehensive value evaluation system for innovative drugs is expected to enhance the efficient use of healthcare resources [3] Group 2 - CITIC Securities reports that the NHSA's ongoing efforts in centralized procurement and negotiation will shift the market focus from low-price competition to quality and cost control, benefiting companies with strong quality systems and cost advantages [4] - The innovative drug sector is anticipated to receive continued policy support, with commercial insurance policies providing additional growth opportunities [4] - By 2025, the domestic innovative drug industry is expected to reach a turning point, transitioning from capital-driven to profit-driven growth, presenting dual opportunities for performance and valuation recovery [4]

Summary of Key Points Core Viewpoint - The financing balance of the Sci-Tech Innovation Board increased by 1.9 billion yuan compared to the previous day, indicating a growing interest from investors in this sector [1]. Financing Balance Overview - As of July 21, the total margin financing balance on the Sci-Tech Innovation Board reached 164.42 billion yuan, with a daily increase of 1.9 billion yuan, marking six consecutive days of growth [1]. - There are 427 stocks with a financing balance exceeding 100 million yuan, and 17 stocks with balances over 1 billion yuan [1]. Stocks with Significant Financing Inflows - The stocks with the highest net financing inflows include: - Ding Tong Technology: 408 million yuan, up by 121 million yuan, with a daily increase of 10.11% [2]. - Lanqi Technology: 3086 million yuan, up by 109.71 million yuan, with a daily decrease of 2.04% [2]. - Chengdu Xian Dao: 394 million yuan, up by 65.78 million yuan, with a daily increase of 6.38% [2]. Sector Performance - The average increase for stocks with net financing inflows exceeding 10 million yuan was 1.28%, with notable gainers including: - Jian Kai Technology: up by 20.00% - Tie Jian Heavy Industry: up by 19.90% - New Rui Shares: up by 16.50% [2]. - The sectors attracting the most financing interest include pharmaceuticals, electronics, and machinery, with 25, 21, and 16 stocks respectively [2]. Financing Balance as a Percentage of Market Value - The average financing balance as a percentage of the circulating market value for stocks with significant net inflows is 3.86% [2]. - The stock with the highest financing balance relative to its market value is Rongbai Technology, with a financing balance of 1.326 billion yuan, accounting for 12.61% of its market value [2]. Notable Stocks with Decreased Financing Balances - Stocks with decreased financing balances include: - SMIC: down by 101 million yuan - Junshi Biosciences: down by 41.39 million yuan - Jinpan Technology: down by 40.12 million yuan [1].

Core Viewpoint - The innovative drug concept stocks have shown significant activity, with Chengdu Xian Dao and Chengda Pharmaceutical both rising over 10% following a meeting by the National Medical Insurance Administration regarding the evaluation of innovative drugs and medical devices [1] Group 1: Stock Performance - Chengdu Xian Dao and Chengda Pharmaceutical both experienced stock increases exceeding 10% [1] - Other companies such as Bai Ao Tai, Sai Sheng Pharmaceutical, Li Zhu Group, Hai Te Biological, Chen Xin Pharmaceutical, and Jian Kang Yuan saw stock rises of over 5% [1] Group 2: Regulatory Developments - The National Medical Insurance Administration held the first session of a series of discussions focused on supporting innovative drugs and medical devices [1] - The discussions centered on the topic of conducting comprehensive value assessments for innovative drugs and medical devices [1]

Group 1 - Haier Air Conditioning's subsidiary terminates investment in a new energy materials project due to economic feasibility concerns stemming from tariff policy adjustments, transportation and exchange rate fluctuations, and intensified market competition [1] - Chengdu XianDao's majority of self-developed new drug projects are in various pre-clinical stages, with significant uncertainty regarding future external transfers [1] - Huafeng Technology plans to raise up to 1 billion yuan through a private placement to fund expansion projects including high-speed line modules and defense connectors [1] Group 2 - Hehe Information expects a revenue increase of 19.15% to 26.13% year-on-year for the first half of 2025, driven by advancements in AI technology and enhanced product competitiveness [2] - Xiamen Tungsten's net profit for the first half of 2025 is reported at 307 million yuan, a year-on-year increase of 27.76%, benefiting from national subsidy policies and increased demand for 3C consumer devices [3] - China Power Construction signed new contracts worth 686.699 billion yuan in the first half of 2025, a year-on-year growth of 5.83%, with energy and power contracts increasing by 12.27% [4] Group 3 - Beilu Zhikong plans to invest approximately 600 million yuan to establish a smart mining driving industrialization base in Nanjing [5] - Zhongshi Technology anticipates a net profit increase of 85.01% to 105.75% for the first half of 2025, driven by recovering market demand in the consumer electronics sector [6] - Yongli Co. intends to establish a joint venture focused on smart pet appliances, with an investment of 2.55 million yuan for a 51% stake [7] Group 4 - Sanquan Foods plans to set up a wholly-owned subsidiary in Hong Kong and invest approximately 280 million Australian dollars to establish a production base in Australia [7] - Yunda Technology's controlling shareholder intends to transfer 10% of the company's shares at a price of 9.01 yuan per share, totaling 400 million yuan [7] - Zhongya Co.'s actual controller plans to reduce their stake by up to 1.27% over the next three months [8] - Delian Group plans to invest up to 60 million yuan of idle funds in securities to enhance cash utilization and returns [9]

证券代码：688222 证券简称：成都先导 公告编号：2025-028 成都先导药物开发股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 所科创板股票异常交易实时监控细则》的有关规定，属于股票交易异常波动。 公司股票交易连续 3 个交易日内（2025 年 7 月 17 日、2025 年 7 月 18 日和 2025 年 7 月 21 日）收盘价格涨幅偏离值累计达到 30%，根据《上海证券交易所交易规 则》、 《上海证券交易所科创板股票异常交易实时监控细则》的有关规定，属于股票 交易异常波动。 二、公司关注并核实的相关情况 行业政策未发生重大调整，生产成本和销售等情况未出现大幅波动、内部生产经营 秩序正常。 不存在正在筹划并购重组、股份发行、债务重组、业务重组、资产剥离和资产注入 等重大事项。公司无应披露而未披露的重大信息。 市场传闻，未发现其他可能对公司股价产生较大影响的重大事件；未发现公司及有 关人员泄露未公开重大信息的情况。 公司董事、监事、高级管理人员不存在买卖公司股 ...

重要内容提示： 一、股票交易异常波动的具体情况 证券代码：688222 证券简称：成都先导 公告编号：2025-028 成都先导药物开发股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司股票交易连续 3 个交易日内（2025 年 7 月 17 日、2025 年 7 月 18 日和 2025 年 7 月 21 日）收盘价格涨幅偏离值累计达到 30%，根据《上海证券交易所交易规 则》、《上海证券交易所科创板股票异常交易实时监控细则》的有关规定，属于股票 交易异常波动。 二、公司关注并核实的相关情况 1 成都先导药物开发股份有限公司（以下简称"公司"）股票交易连续三个交易 日内（2025 年 7 月 17 日、2025 年 7 月 18 日和 2025 年 7 月 21 日）收盘价格 涨幅偏离值累计达到 30%，根据《上海证券交易所交易规则》、《上海证券交易 所科创板股票异常交易实时监控细则》的有关规定，属于股票交易异常波动。 经公司自查，并发函问询控股股东、实际控制人，确认截至本公告披露日 ...

Group 1 - The company's stock price has experienced an abnormal fluctuation, with a cumulative increase of 30% over three consecutive trading days (July 17, July 18, and July 21, 2025) [1] - Most of the company's self-developed new drug projects are currently in various stages of preclinical development, indicating significant uncertainty in their progress [1] - There is a major uncertainty regarding the potential for external transfer of these drug projects in the future [1]

Group 1 - The CRO concept index rose by 2.61%, ranking 10th among concept sectors, with 55 stocks increasing in value, including Chengdu Xian Dao which hit a 20% limit up [1] - Leading gainers in the CRO sector included MediWest, Haitai Biological, and Boji Pharmaceutical, with increases of 19.00%, 11.93%, and 9.50% respectively [1] - The sector saw a net inflow of 447 million yuan from main funds, with 30 stocks receiving net inflows, and 8 stocks exceeding 50 million yuan in net inflow [2] Group 2 - Major contributors to net inflow included WuXi AppTec with 203 million yuan, followed by Zhaoyan New Drug, Chengdu Xian Dao, and MediWest with net inflows of 130 million yuan, 126 million yuan, and 107 million yuan respectively [2] - The net inflow ratios for Zhaoyan New Drug, Chengdu Xian Dao, and MediWest were 13.04%, 12.33%, and 11.88% respectively [3] - The trading volume for WuXi AppTec was 20.33 million yuan with a turnover rate of 1.67% [3] Group 3 - The stock Boji Pharmaceutical had a significant increase of 9.50% with a trading volume of 21.40 million yuan [6] - The stock ST Unnamed experienced the largest decline of 5.01% with a trading volume of 96.79 million yuan [6] - The overall performance of the CRO sector indicates strong investor interest and potential growth opportunities within the industry [2][3]